|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.03 AUD | +1.58% |
|
-5.09% | +43.12% |
| 06:12pm | Telix Pharmaceuticals Doses First Patients in Phase Two Trial for Prostate Cancer Therapy | MT |
| 07-15 | Telix Reports First Patients Dosing in Prostate Cancer Trial | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Neutral |
| Resistance | 17.38 | 17.38 | 18.33 |
| Spread/Res. | -7.77% | -7.77% | -12.55% |
| Spread/Supp. | +12.81% | +31.39% | +82.99% |
| Support | 14.21 | 12.2 | 8.76 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- TLX Stock
- Charts Telix Pharmaceuticals Limited
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
